Biofuels Digest on Solazyme IPO
The last part of the text of the Biofuels Digest post on the Solazyme IPO:
Ultimately, at oil company margins and price-revenue ratios (see Shell’s data), survivor companies, we believe, will have a minimum value of $2.74 billion. So there’s around a 66 percent “not going to make it to prime time” discount on Solazyme, the way we see it.
In the patent area, note the previous IPBiz post
US 7,905,930 to Genifuel : sugar to heterotrophs to oil
Ultimately, at oil company margins and price-revenue ratios (see Shell’s data), survivor companies, we believe, will have a minimum value of $2.74 billion. So there’s around a 66 percent “not going to make it to prime time” discount on Solazyme, the way we see it.
In the patent area, note the previous IPBiz post
US 7,905,930 to Genifuel : sugar to heterotrophs to oil
posted by Lawrence B. Ebert at 7:02 AM
0 Comments:
Post a Comment
<< Home